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Background/Aim: The lives of about 257 million people in the world are being affected by chronic 
hepatitis B (CHB), and this contagious disease is gradually pushing them closer to the edge of death 
caused by cirrhosis and hepatocellular carcinoma. Ontario is closely connected to the rest of the world; 
more than 40% of the annual population growth over the past decade has come from immigrants. 
Addressing hepatitis B and achieving the World Health Organization (WHO)’s hepatitis elimination 
goals are vital. Tenofovir alafenamide (TAF) has been approved for treating CHB due to a proposed 
better safety profile in comparison to current therapies. However, its cost-effectiveness remains 
unknown. The aim of this thesis was to assess the health and economic impact of TAF and other 
treatments of CHB in Ontario. 
Methods: Two types of health policy models were employed to compare strategies involving entecavir 
(ETV), tenofovir disoproxil fumarate (TDF), and TAF. 1) A state-transition model (STM) based on the 
natural history of CHB and the published literature was developed to evaluate the cost-effectiveness of 
the treatment strategies for hepatitis B envelope antigen (HBeAg)-positive and HBeAg-negative CHB 
patients from an Ontario Ministry of Health perspective. It adopted a lifetime time horizon, and 
outcomes measured were predicted number of liver-related disease and deaths, costs (2018 Canadian 
dollars), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). 2) An 
agent-based model (ABM) that accommodates differential selectivity, behavior, and network properties 
was developed to predict the impact of the treatment-as-prevention options on the incidence and 
prevalence of hepatitis B virus (HBV)-related health outcomes in Ontario over the next decade. We 
simulated the entire Ontario population, stratified by age, gender, residential address, and immigration 
status. Parameters were estimated from literature-derived estimates regarding Ontario demographics, 
epidemiology, and sexual behavior. Historical Ontario HBV data were used for calibration. 
Results: 1) The STM found that TAF-containing strategies are unlikely to be a rational choice for 
treating CHB infections. For HBeAg-positive patients, TAF followed by ETV generated an additional 
0.16 QALYs/person at an additional cost of $14,836.18 with an ICER of $94,142.71/QALY compared 
with TDF followed by ETV. Only 28.7% of the iterations showed that it is the optimal strategy with 
$50,000 willingness-to-pay threshold. For HBeAg-negative patients, ETV followed by TAF would 
prevent an additional 13 liver-related deaths per 1,000 CHB patients treated compared with TDF 
followed by ETV. It generated an additional 0.13 QALYs/person at an additional cost of $59,776.53 
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with an ICER of $461,162.21/QALY compared with TDF followed by ETV. 2) We calibrated the 
ABM-simulated number of reported acute hepatitis B (AHB) infections with the historical reported 
cases in Ontario. After extensive calibration and validation processes, our model showed a good match 
with the real-world observations. The ABM predicted that the actual prevalence of CHB in Ontario 
would decrease by 11.5% from 2017 to 2030 if all CHB patients eligible and ready for treatment begin 
to receive TDF followed by ETV or TAF followed by ETV after 2016. The reported incidence of AHB 
and the actual incidence of liver-related death are expected to fall by 48.9% and rise by 12.3% from 
2017 to 2030, respectively. TAF followed by ETV was not found to be significantly different from 
TDF followed by ETV in reducing the prevalence and incidence of HBV-related health outcomes. 
Conclusions: TAF is not cost-effective at its current cost. A 33.4% reduction in price would be required 
to make it cost-effective for HBeAg-positive patients with a $50,000 willingness-to-pay threshold. The 
percentages of decline in new CHB cases and liver-related deaths from 2017 to 2030 would be 37.8% 
and 77.3% lower than the percentages that the WHO is targeting, respectively. Ontario is unable to 
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Chronic hepatitis B (CHB) is a viral infection that affects the liver, causing approximately 887,000 
deaths worldwide in 2015.1 It is a silent disease; most people are not aware of it when they are infected. 
As CHB can progress into cirrhosis or hepatocellular carcinoma (HCC) from long-term infection,2 most 
people infected and diagnosed with it must be on lifelong treatment.1 
1.1 Hepatitis B Virus Transmission Mode and Prevalence 
Hepatitis B virus (HBV) can be transmitted through the blood, saliva, and other body fluids from an 
infected person.1 Although effective hepatitis B vaccines have been available since 1982, new HBV 
infections are still common.2 It has been estimated that the lives of 257 million people in the world are 
being affected by CHB,1 and approximately 111,800 people with HBV are living in Canada.3 The HBV 
infection rate in Canada is less than 1% of the Canadian population;3 however, the prevalence of 
hepatitis B should not be ignored. More than one-fifth of the Canadian population was born abroad,4 
and most of the immigrants over the past decade came from regions with high-prevalence of hepatitis 
B, such as Asia and Africa.1,4 
1.2 Natural History of Hepatitis B 
People infected with HBV will initially develop acute hepatitis B (AHB).2 The persistence of hepatitis 
B surface antigen (HBsAg) in the serum for at least six months is a major indicator of chronic infection.1 
The majority of patients with chronic infection are infected at birth or in early childhood.5 However, a 
small proportion of patients develop chronic infection from AHB acquired during adulthood.2 
CHB infection stages can be generally classified into four phases: the immune tolerant phase, 
immune clearance phase, inactive carrier phase, and reactivation phase.2,5-7 Patients in the immune 
tolerant phase have high HBV viral load, normal alanine aminotransferase (ALT) levels, and minimal 
liver damage.2,6,7 When the tolerogenic effect is lost during the first phase, patients enter the immune 
clearance phase.2 Their immune system realizes that HBV is foreign, and the resulting immune response 
causes liver inflammation.7 Hence, both elevated HBV viral load and ALT levels are the major features 
of this phase.2 Hepatitis B envelope antigen (HBeAg) seroconversion may occur in patients with 
HBeAg-positive CHB.7 The disease then enters the inactive carrier phase.2,7 HBV viral load drops to 
an undetectable level, and ALT levels become normal, indicating mild or no liver injury.2 Even if CHB 
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patients enter the inactive carrier phase, HBeAg reversion is still possible and might happen multiple 
times in the future.6,7 They can also enter the reactivation phase and develop HBeAg-negative CHB,5 
which has a higher incidence of cirrhosis.2 A very small minority of patients may develop HBsAg loss 
and completely recover from this chronic disease.5 
About 2% to 10% of patients with CHB develop cirrhosis every year.8 Subsequently, they may 
further deteriorate to decompensated cirrhosis (DC) or HCC at an annual rate of 5% to 10%.8 The 
annual chance of death for patients with DC or HCC is 20% to 50%.8 
1.3 Hepatitis B Virus Screening and Vaccination Policy 
HBV screening for pregnant women, immigrants from high-prevalence regions of HBV, and other 
high-risk groups, such as those who have percutaneous or mucosal exposure to HBV, was suggested 
by the National Advisory Committee on Immunization (NACI);9 however, only screening of pregnant 
women was implemented in Canada.10 People in the immigration process are not required to receive 
HBsAg testing.11 NACI also recommended HBV vaccination for all infants, children under the age of 
18, and people at increased risk of HBV infection such as those who have unprotected sexual contacts 
with new partners.9 Infants born to a mother with hepatitis B should be vaccinated within 12 hours of 
birth.9 Since 1994, Ontario has initiated a routine HBV vaccination program for seventh-grade 
students,9 and the completion rate has been very high (78% to 97%).10 
1.4 Treatment of Chronic Hepatitis B 
The primary goals of treating CHB are to achieve sustained suppression of HBV replication and liver 
disease remission and to prevent serious outcomes such as cirrhosis and HCC.6 The treatment of 
HBeAg-positive CHB ends when HBeAg seroconversion occurs, but the endpoint of treating HBeAg-
negative CHB is unknown.6 Effective drugs with a high barrier to resistance, such as entecavir (ETV) 
and tenofovir disoproxil fumarate (TDF), have been developed. The resistance rate of ETV in 
treatment-naïve patients is below 1%,12 and it may be effective for HBeAg-positive CHB patients with 
resistance to lamivudine (LAM).8 While resistance to TDF has not yet been observed,13-15 its long-term 
use may have a negative impact on the bones and kidneys.14 Both TDF and ETV have lost their patents, 
allowing the availability of more affordable generic versions.16 
ETV and TDF were recommended by the American Association for the Study of Liver Diseases 
(AASLD), the World Health Organization (WHO), and a number of guidelines and analyses as the 
most potent and cost-effective drugs to suppress HBV.1,17-24 However, the approval of a novel prodrug 
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of TDF, tenofovir alafenamide (TAF), by the U.S. Food and Drug Administration for the treatment of 
CHB in November 2016 may impact these recommendations. Two randomized controlled trials were 
recently published comparing the efficacy of TAF and TDF, where TAF was found to be able to deliver 
the active metabolite to target cells more efficiently than TDF at a much lower dose, thereby reducing 
bone and renal toxic effects caused by systemic exposure.14,15 Similar to TDF, its barrier to resistance 
is presumably very high.14,15,25 However, its comparative cost-effectiveness with other treatments 
remains unknown. 
At present, TDF and ETV are funded by the Ontario Drug Benefit Program.16 Although TAF has 
been identified as a preferred therapy for patients with CHB in the guidelines released by the AASLD 
and the European Association for the Study of the Liver (EASL) due to clinical benefits,17,26 it has not 
been listed as a reimbursed drug in Ontario.16 The WHO’s global hepatitis strategy calls for a 90% 
reduction in new CHB cases, a 65% reduction in CHB deaths, and an 80% treatment rate on eligible 
CHB patients worldwide by 2030,27 and the Canadian government is committed to achieving these 
goals.28 How TAF is going to affect the relative cost-effectiveness of each treatment option, and 
whether it is able to help us achieve the goals set by the WHO, need to be examined. 
1.5 Health Policy Models 
Health policy models are mathematical simulation tools that provide a platform to combine evidence 
of effectiveness, safety, and cost and provide support in analyzing the potential impact of health 
strategies for a given amount of expenditure. They are being increasingly relied on by healthcare 
providers and governments to make rational decisions about adopting healthcare programs and 
reimbursing new drugs. The benefit of treating some diseases such as CHB may only be observed after 
a long period of time. As such, health policy modeling is the only practical option for estimating the 
long-term impact of CHB treatment strategies. The two kinds of models that are suitable to simulate 
the potential impact of strategies on the development of CHB are the state-transition model (STM) and 
the agent-based model (ABM),29,30 which are described below. 
1.6 Knowledge Gaps and Objectives 
Two knowledge gaps were identified. 1) Since the new drug, TAF, was approved for the treatment of 
CHB, there has not been any cost-effectiveness analysis in the literature involving it. 2) The prevalence 
of HBV is quite high in some regions such as Asia, and multiple antiviral therapies for treating CHB 
have been available in Canada before the year 2000;1,18 however, there is no suitable infectious disease 
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model for hepatitis B that can be used to properly assess the impact of treatment as prevention until 
now. 
The aim of this thesis was to assess the health and economic impact of TAF and other treatments of 
CHB in Ontario. Specifically, 1) an STM was employed to evaluate the cost-effectiveness of the 
available CHB treatment options from a provincial Ministry of Health perspective; and 2) an ABM was 
employed to predict the impact of the treatment-as-prevention options on the incidence and prevalence 
of HBV-related health outcomes in Ontario over the next decade (Figure 1.1). Two independent studies 
were conducted based on these two models, respectively. The STM and its results are explained in the 
following chapter, the ABM and its outcomes are explained in Chapter 3, and the last chapter is the 
overall conclusion of this thesis. 
 
Figure 1.1 Objectives of the Models 
 





STMs are widely used in health-economic assessments.29 The natural history of the disease is always 
considered to be the focus of building an STM. By conceptualizing complex medical problems into 
several mutually exclusive health states and simulating the transitions of a cohort or individuals among 
these states over a given number of cycles, parameters for decision making, such as life expectancy and 
overall costs, can be easily estimated. The advantage of STMs is that they are relatively easy to build 
and inspect if the number of health states is not large.29 Its main disadvantage is that it is difficult to 
associate transition probabilities with the past experience of the simulated individuals, which limits its 
clinical applications.29 An STM is suitable if the decision problem can be broken down into states, the 
target population is a closed cohort, and the interactions between individuals are less important.29 
2.1 Review of Previous Cost-effectiveness Analyses 
Numerous studies around the world have assessed the cost-effectiveness of available treatments on 
CHB infections, and a large proportion of them concluded that either TDF or ETV is the optimal 
strategy.19-24 Three of these studies were conducted in Canada between 2011 and 2015.19-21 One of them 
was done by Jing He et al..19 They constructed an STM to project the lifetime health outcomes and costs 
associated with LAM, telbivudine, ETV, and TDF. In their model, patients who achieved viral 
suppression had lower disease progression rates than the others. They also allowed patients to switch 
to rescue therapies recommended by the Canadian and AASLD guidelines when viral resistance 
occurred,17,31 and assumed that the resistance rate of the rescue therapies is zero. However, their model 
oversimplified the natural history of CHB. Their target patient population was limited to an HBeAg-
positive cohort, and all HBeAg-negative health states were excluded from their model. The chance of 
HBeAg reactivation was included in the probability of HBeAg reversion, which means that HBeAg-
negative CHB was assumed to be identical to HBeAg-positive CHB including the ability to become 
inactivated. Furthermore, the treatment strategies in their model were not applied to the state of 
compensated cirrhosis (CC), and HBeAg seroconversion cannot occur in CHB patients with cirrhosis. 
As a result, they found that TDF dominated all the other strategies evaluated. 
Another study done by Helen Dakin et al. was based on a sophisticated STM.20 They considered 
three cohorts: treatment-naïve non-cirrhotic CHB patients, treatment-naïve cirrhotic CHB patients, and 
LAM-resistant CHB patients with or without CC. HBeAg-positive and HBeAg-negative patients were 
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not evaluated separately; both of them were included in each cohort with a certain percentage. TDF, 
adefovir, ETV, LAM, and their most commonly used combinations (up to three treatments in sequence) 
were compared. Switching treatment occurred when viral suppression failed to be achieved in certain 
cases after one year or when drug resistance developed. Unlike the model developed by He et al.,19 
Dakin et al. not only considered HBeAg-negative health states but also divided severe liver disease 
states (such as DC and liver transplant) into two health states based on the HBeAg status. Treatments 
were applied to the CC states as well as the CHB states. However, they also considered some parameters 
that may not be significant, such as the relative risk of HBeAg seroconversion in patients treated for 
one year versus treated for more than one year. As a result, they found that TDF followed by LAM is 
the most cost-effective strategy for CHB patients with or without cirrhosis if the willingness-to-pay 
threshold was assumed to be $50,000/QALY. For all of the cohorts considered, strategies with TDF as 
the first treatment of the sequence were more effective than the other strategies. However, sensitivity 
analyses identified that the conclusions may be altered due to changes in 12 parameters including the 
time horizon, HBeAg seroconversion rates, disease progression rates, and discount rate. 
An STM constructed by the Ontario Drug Policy Research Network had many similarities to the 
model developed by Dakin et al..20,21 The major difference was that the DC state, liver transplant state, 
and post-liver transplant state were no longer separated based on HBeAg status. They considered four 
cohorts; the target population was divided according to their HBeAg status and the presence or absence 
of cirrhosis. TDF, ETV, LAM, and their sequential combinations were compared, and switching 
treatment was allowed when drug resistance or non-response to treatment occurred. Only two 
treatments were allowed in each strategy. In contrast to the previous two analyses,19,20 this study found 
that TDF as the first-line therapy would only be optimal for HBeAg-positive CHB patients with 
cirrhosis. Initiating treatment with LAM would be relatively cost-effective for HBeAg-positive CHB 
patients without cirrhosis, and none of the treatment strategies considered was cost-effective for 
HBeAg-negative CHB patients regardless of cirrhosis status. 
The values of the parameters used in the articles described above no longer represent their present 
values; the cost of TDF and ETV nowadays is almost one-third of the prices used in their models 
because of the availability of the generic versions.16,19-21 Although these studies have produced valuable 
research methods and conclusions, their results may no longer reflect the current situation. Furthermore, 




To address these knowledge gaps, we developed an STM to evaluate the health and economic impact 
of TAF in the context of currently reimbursed CHB treatments. 
2.2.1 Type of Economic Evaluation 
The analysis is a cost-utility analysis conducted from an Ontario Ministry of Health perspective. The 
cost-effectiveness of the strategies was assessed using the predicted number of liver-related diseases 
and deaths, costs (2018 Canadian dollars), quality-adjusted life years (QALYs), and incremental cost-
effectiveness ratios (ICERs). 
2.2.2 Cohorts 
Two treatment-naïve cohorts were analyzed separately taking into account their different disease 
progression patterns: one consisted of HBeAg-positive non-cirrhotic CHB patients, while the other 
included HBeAg-negative non-cirrhotic CHB patients. Consistent with the published randomized 
controlled trials on TAF,14,15 the average ages of the HBeAg-positive and HBeAg-negative cohorts at 
the beginning of treatment in the base case analysis were 38 and 45 years, respectively. In the sensitivity 
analyses, the effect of raising and reducing the starting age of treatment was determined. 
2.2.3 Strategies 
Three antiviral therapies recommended by the AASLD guidelines were considered: ETV (0.5mg tablet 
once daily), TDF (300mg tablet once daily), and TAF (25mg tablet once daily).17 If a drug is unable to 
suppress the virus, or if the patients developed resistance to the drug during treatment, the patients will 
be treated with an alternative therapy. To simplify the complexity, we limited each patient to a 
maximum number of two types of antiviral treatments.21 We also assumed that each case of drug 
resistance required an additional visit to a specialist physician. Drug resistance status was assumed to 
have no effect on the utilities in the base case analysis, and best supportive care (BSC) was defined as 
careful monitoring without antiviral treatment.20 As recommended by the AASLD, seven treatment 
strategies were compared:17 
1) TAF followed by BSC (TAF→BSC); 
2) TDF followed by BSC (TDF→BSC); 
3) ETV followed by BSC (ETV→BSC); 
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4) TAF followed by ETV and followed by BSC (TAF→ETV→BSC); 
5) TDF followed by ETV and followed by BSC (TDF→ETV→BSC); 
6) ETV followed by TAF and followed by BSC (ETV→TAF→BSC); and 
7) ETV followed by TDF and followed by BSC (ETV→TDF→BSC). 
2.2.4 Model Structure and Implementation 
According to the natural history of CHB, multiple states of disease progression and a long-term time 
horizon need to be considered in the model. In order to achieve recurrence and complex transitions 
between the states, an STM was constructed using TreeAge Pro Suite 2019 software (TreeAge 
Software, Inc., Williamstown, MA, USA).29 Thirty-three mutually exclusive health states were 
incorporated into the model, including one HBsAg loss state, thirteen non-cirrhotic CHB states, thirteen 
CC states, four severe liver disease states, and two death states. A simplified version of the model is 
shown in Figure 2.1. All patients in a non-death state had a certain probability to die due to reasons not 
associated with HBV.32 
The length of each cycle was defined to be one year, and the disease status of each patient was 
simulated based on annual parameters. Patients can move to another health state or remain in their 
current state within each cycle depending on the annual state-transition probabilities. The costs and 
utilities of the patients at each time point were recorded for further calculations. The time horizon of 
the model was lifetime, which means that simulations end when all patients within the model have died. 
Cost and effectiveness values were discounted at an annual rate of 1.5% in the base case analysis.33 
For the HBeAg-positive cohort, the model assumed that treatment is only applied to members with 
CHB or CC according to the AASLD guidelines.17 When HBeAg reversion or hepatitis B reactivation 
occurs in patients in the inactive carrier phase, the model assumed that they will continue to be treated 
with the drug they used prior to entering that phase. For the HBeAg-negative cohort, we assumed that 
treatment is only applied to members with HBeAg-negative CHB or HBeAg-negative CC.17 A 
treatment was terminated when HBeAg seroconversion is achieved, drug resistance is developed, or it 
is no longer able to suppress the virus. 
Common types of serious adverse events (SAEs) of TAF, TDF, and ETV include urine erythrocytes, 




Figure 2.1 State-transition Model of Chronic Hepatitis B Progression 
 
BSC, best supportive care; CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompensated cirrhosis; HBeAg-, 
hepatitis B envelope antigen-negative; HBeAg+, hepatitis B envelope antigen-positive; HBsAg, hepatitis B surface antigen; 
HCC, hepatocellular carcinoma. 
 
year of taking a drug, and patients require two additional physician visits whenever an SAE occurs. 
Patients with SAEs were assumed to be closely monitored without discontinuing the current drug and 
switching to another.17 Furthermore, the negative impact of SAEs on health utilities were also 
considered by the model. 
2.2.5 Model Probabilities 
All probabilities and ratios regarding health outcomes were obtained from the published literature and 
a recent systematic review and network meta-analysis as shown in Table 2.1.12-15,25,32,35-58 If a treatment 
failed to achieve viral suppression, we assumed that this is equivalent to no virologic response. 
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Otherwise, the treatment is considered effective, and patients have less chance of developing CC, DC, 
and HCC while being treated.55-57 
2.2.6 Costs 
The annual cost of the HBsAg loss state was assumed to be the same as that of the average healthcare 
cost for an uninfected individual.59 Additional annual costs regarding the health states were direct 
medical costs collected from the published literature (Table 2.1).60 The brand price of TAF was obtained 
from the Canadian Agency for Drugs and Technologies in Health Common Drug Review,61 and the 
costs of the other drugs were the generic prices obtained from the Ontario Drug Benefit Formulary.16 
These costs exclude professional fees and mark-ups on the drug costs that are charged by dispensing 
pharmacies. Additionally, these costs are considered the actual acquisition costs of the treatment, as the 
Ontario legislation prohibits cost rebates provided by a manufacturer pertaining to the cost by the 
operator of a pharmacy. Furthermore, the consultation fee for gastroenterologists was obtained from 
Ontario Ministry of Health and Long-Term Care Schedule of Benefits (Physician Services Under the 
Health Insurance Act).62 All costs were inflated to 2018 prices using the Canadian Consumer Price 
Index.63 
2.2.7 Utilities 
The utilities of the health states were obtained from a study of more than four hundred CHB patients 
with or without treatment (Table 2.1).64 Health Utility Index Mark 3 (HUI3) scores were the default 
values adopted in the models, with 1 representing perfect health and 0 representing death. EuroQol-5 
Dimension (EQ-5D) scores were only considered in the sensitivity analyses. We assumed that all non-
cirrhotic CHB states besides inactive CHB state have the same utility score, and all CC states have the 
same utility score. The utility of liver transplant in the first year was assumed to be the same as that of 
liver transplant after the first year. We also assumed that patients in the inactive CHB state and HBsAg 
loss state have the same utilities as the general Canadian adult population. 
2.2.8 Sensitivity Analyses 
One-way sensitivity analyses were conducted on the majority of parameters used by the model, and the 
ranges of most parameters analyzed were their credible intervals obtained from their sources (Table 
2.1). 100,000 iterations of Monte Carlo simulation were conducted for each probabilistic sensitivity 
analysis (PSA) to determine the overall impact of parameter uncertainty on the results. 
11 
 
Table 2.1 Model Inputs for the State-transition Model 
State-transition Probabilities 
Parameter Baseline Low High Distribution SD†   Source 
HBeAg+ CHB (without treatment) to Inactive CHB 0.0213 0.0079 0.0551 Beta 0.0173  14, 35 
HBeAg+ CHB (without treatment) to HBeAg+ CC 0.044 0.022 0.088 Beta 0.0224  37, 38, 48, 49 
Inactive CHB to HBsAg Loss 0.008 0.0005 0.02 Beta 0.0061  36-38 
Inactive CHB to HBeAg+ CHB 0.0048 0.004 0.018 Beta 0.0067  36-38, 52 
Inactive CHB to HBeAg- CHB 0.0254 0.02 0.05 Beta 0.0126  38, 52, 53 
Inactive CHB to Inactive CC 0.001 0.001 0.002 Beta 0.0005  37, 38, 52 
HBeAg- CHB (without treatment) to HBeAg- CC 0.029 0.015 0.058 Beta 0.0148  38, 50-52 
HBeAg+ CC (without treatment) to Inactive CC 0.1 0.07 0.13 Beta 0.0153  Assume same as Non-cirrhotic CHB 
HBeAg+ CC (without treatment) to DC 0.073 0.035 0.1 Beta 0.0194  38, 44-46 
HBeAg+ CC (without treatment) to HCC 0.034 0.01 0.12 Beta 0.0439  38, 42-44 
Inactive CC to HBsAg Loss 0.008 0.0005 0.02 Beta 0.0061  36-38 
Inactive CC to HBeAg+ CC 0.0048 0.008 0.018 Beta 0.0067  36-38 
Inactive CC to HBeAg- CC 0.0254 0.02 0.05 Beta 0.0126  38, 52, 53 
Inactive CC to DC 0.008 0.004 0.016 Beta 0.0041  37, 38, 47 
Inactive CC to HCC 0.022 0.011 0.044 Beta 0.0112  37, 38, 47 
HBeAg- CC (without treatment) to DC 0.073 0.035 0.1 Beta 0.0194  38, 44-46 
HBeAg- CC (without treatment) to HCC 0.037 0.01 0.12 Beta 0.0423  38, 41-44 
DC to HCC 0.06 0.01 0.113 Beta 0.0270  38-41 
DC to Liver Transplant 0.05 0 0.4 Beta 0.1786  38-40 
DC to Disease Death 0.173 0.058 0.221 Beta 0.0587  38-40 
HCC to Liver Transplant 0.15 0.05 0.4 Beta 0.1276  38-40 




Table 2.1 Continued 
State-transition Probabilities 
Parameter Baseline Low High Distribution SD†   Source 
Liver Transplant to Disease Death 0.142 0.124 0.159 Beta 0.0092  54 
Post-liver Transplant to Disease Death 0.034 0.024 0.043 Beta 0.0051   54 
Relative Risk of CC for CHB Patients with Treatment vs No Treatment 0.308 0.231 0.385 Gamma 0.0393  55 
Relative Risk of DC for CC Patients with Treatment vs No Treatment 0.5209 0.391 0.651 Gamma 0.0664  55 
Relative Risk of HCC for CC Patients with Treatment vs No Treatment 0.3857 0.2892‡ 0.4821§ Gamma 0.0492   56, 57 
Treatment-related Probabilities 
Parameter Baseline Low High Distribution SD†   Source 
ETV - HBeAg Seroconversion 0.0561 0.0245 0.1172 Beta 0.0311  14, 35 
ETV - Viral Suppression (HBeAg+ patients) 0.4788 0.2513 0.7247 Beta 0.1255  14, 35 
ETV - Viral Suppression (HBeAg- patients) 0.7596 0.0194 0.9968 Beta 0.3776  15, 35 
ETV - Resistance 0.0020 0.0015‡ 0.0025§ Beta 0.0003  12 
ETV - SAE 0.048 0.025 0.082 Beta 0.0173   35, 58 
TDF - HBeAg Seroconversion 0.0809 0.0434 0.1422 Beta 0.0313  14, 35 
TDF - Viral Suppression (HBeAg+ patients) 0.6675 0.4703 0.8230 Beta 0.1006  14, 35 
TDF - Viral Suppression (HBeAg- patients) 0.9298 0.8570 0.9683 Beta 0.0372  15, 35 
TDF - Resistance 0 0 0    13-15 
TDF - SAE 0.071 0.031 0.139 Beta 0.0347   35, 58 
TAF - HBeAg Seroconversion 0.1027 0.0770‡ 0.1283§ Beta 0.0131  14 
TAF - Viral Suppression (HBeAg+ patients) 0.6386 0.4789‡ 0.7982§ Beta 0.0814  14 
TAF - Viral Suppression (HBeAg- patients) 0.9404 0.7053‡ 1.0000§ Beta 0.1199  15 
TAF - Resistance 0 0 0    14, 15, 25 




Table 2.1 Continued 
Costs 
Parameter Baseline Low High Distribution SD†   Source 
Average Healthcare for an Uninfected Individual $6,428.39 $4,821.29‡ $8,035.49§ Gamma 819.9479  59 
Additional Cost of Non-cirrhotic CHB $1,164.86 $1,029.83 $1,347.64 Gamma 93.2536  60 
Additional Cost of CC $2,550.70 $1,722.74 $4,759.02 Gamma 1,126.6986  60 
Additional Cost of DC $15,315.08 $11,333.54 $22,353.37 Gamma 3,590.9603  60 
Additional Cost of HCC $18,209.51 $14,469.40 $23,443.21 Gamma 2,670.2548  60 
Additional Cost of Liver Transplant $135,126.83 $128,664.16 $145,721.09 Gamma 5,405.2304  60 
Additional Cost of Transplant Care after the First Year $52,162.40 $45,616.53 $62,863.04 Gamma 5,459.5123   60 
Unit Price of ETV (0.5mg tablet) $5.50 $4.13‡ $6.88§ Gamma 0.7015  16 
Unit Price of TDF (300mg tablet) $4.89 $3.67‡ $6.11§ Gamma 0.6235  16 
Unit Price of TAF (25mg tablet) $19.55 $14.67‡ $24.44§ Gamma 2.4941   61 
Consultant Visit $165.43 $124.07‡ $206.79§ Gamma 21.1011   62 
Utilities 
Parameter Baseline Low High Distribution SD†   Source 
Canadian Population Norm (HUI3) 0.93 0.85 1.00 Beta 0.0408  64 
Canadian Population Norm (EQ-5D) 0.92 0.91 0.94 Beta 0.0102  Assume same as Non-cirrhotic CHB 
Non-cirrhotic CHB (HUI3) 0.87 0.85 0.88 Beta 0.0102  64 
Non-cirrhotic CHB (EQ-5D) 0.92 0.91 0.94 Beta 0.0102  64 
CC (HUI3) 0.81 0.75 0.86 Beta 0.0306  64 
CC (EQ-5D) 0.88 0.85 0.92 Beta 0.0204  64 
DC (HUI3) 0.49 0.22 0.75 Beta 0.1378  64 
DC (EQ-5D) 0.73 0.39 1.00 Beta 0.1735  64 
HCC (HUI3) 0.85 0.76 0.95 Beta 0.0510  64 
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Table 2.1 Continued 
Utilities 
Parameter Baseline Low High Distribution SD†   Source 
HCC (EQ-5D) 0.81 0.67 0.94 Beta 0.0714  64 
Post-liver Transplant (HUI3) 0.72 0.60 0.83 Beta 0.0612  64 
Post-liver Transplant (EQ-5D) 0.84 0.77 0.91 Beta 0.0357   64 
Drug Resistance (disutility) 0.00 0.00 0.10       Assumption 
SAE (disutility) 0.05 0.0375‡ 0.0625§ Beta 0.0064  Assumption 
Other Parameters 
Parameter Baseline Low High Distribution SD†   Source 
Discount Rate 0.015 0 0.05    33 
Treatment Starting Age (HBeAg+ patients) 38 29‡ 48§ Gamma 5.1020  14 
Treatment Starting Age (HBeAg- patients) 45 34‡ 56§ Gamma 5.6122   15 
 
†Estimated based on its low and high values; ‡75% of its baseline value; §125% of its baseline value. 
CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompensated cirrhosis; EQ-5D, EuroQol-5 Dimension; ETV, entecavir; HBeAg, hepatitis B envelope antigen;  
HBeAg-, hepatitis B envelope antigen-negative; HBeAg+, hepatitis B envelope antigen-positive; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HUI3, Health 






An article published in 2012 reported that the lifetime risk of HCC in HBV carriers is about 15% to 
40%.65 For validation purposes, 1,000,000 trials of microsimulation were carried out on our model and 
estimated that approximately 22.9% of those initiated with HBeAg-positive non-cirrhotic CHB had 
developed HCC in their life (assuming they had the same chance to receive any of the seven treatment 
strategies considered in our study), which is compatible with the values stated in that article. 
Furthermore, the estimated percentage of disease death caused by HCC was around 41.2%, which 
closely matched with the percentage (46%) indicated from a study based on European data.66 
2.3.2 Base Case 
For the HBeAg-positive cohort, 1,000,000 trials of microsimulation were carried out using the base 
case parameters and found that TAF→ETV→BSC would prevent an additional 6 cases of HCC, 8 cases 
of DC, and 11 cases of liver-related death (including 4 deaths caused by HCC and 5 deaths caused by 
DC) per 1,000 CHB patients treated compared with TDF→ETV→BSC (Table A.1). It generated an 
additional 0.16 QALYs/person at an additional cost of $14,836.18 with an ICER of $94,142.71/QALY 
compared with TDF→ETV→BSC (Table 2.2). TAF→ETV→BSC was the most effective treatment 
strategy in terms of QALYs, likely due to the high HBeAg seroconversion rate of TAF. However, all 
strategies involving TAF were much more expensive than the others since the price of TAF is roughly 
four times the price of the other drugs considered. On the other hand, ETV→TDF→BSC was almost 
equally effective as TDF→ETV→BSC in terms of QALYs, but cost an additional $226.66 compared 
with TDF→ETV→BSC. ETV→TDF→BSC, ETV→BSC, TAF→BSC, and ETV→TAF→BSC were 
absolutely dominated since they were more expensive and less effective than some of the others. 
Therefore, TDF→ETV→BSC and TAF→ETV→BSC are likely to be the most cost-effective treatment 
strategies for HBeAg-positive CHB patients at a willingness-to-pay threshold of $50,000/QALY and 
$100,000/QALY, respectively. 
For the HBeAg-negative cohort, TDF→ETV→BSC would prevent an additional 17 cases of HCC, 
22 cases of DC, and 32 cases of liver-related death (including 14 deaths caused by HCC and 14 deaths 
caused by DC) per 1,000 CHB patients treated compared with TDF→BSC (Table A.1). It generated an 




Table 2.2 Base Case Cost-effectiveness Results 
HBeAg-positive Cohort 
Strategy Costs ΔCosts QALYs ΔQALYs ICER ($/QALY) 
TDF→BSC $274,743.42  22.8618   
TDF→ETV→BSC $276,409.87 $1,666.46 23.5859 0.7241 2,301.27 
TAF→ETV→BSC $291,246.05 $14,836.18 23.7435 0.1576 94,142.71 
Absolutely Dominated Strategies (all referencing TDF→BSC) 
ETV→BSC $275,065.00 $321.58 22.0516 -0.8102 -396.92 
ETV→TDF→BSC $276,636.53 $1,893.11 23.5842 0.7224 2,620.63 
TAF→BSC $289,595.47 $14,852.05 23.0378 0.1760 84,384.47 
ETV→TAF→BSC $293,914.91 $19,171.49 23.7328 0.8711 22,009.56 
HBeAg-negative Cohort 
Strategy Costs ΔCosts QALYs ΔQALYs ICER ($/QALY) 
ETV→BSC $252,171.57  20.6444   
TDF→BSC $259,274.75 $7,103.18 21.7453 1.1009 6,452.03 
TDF→ETV→BSC $263,141.73 $3,866.98 22.1941 0.4488 8,616.22 
ETV→TAF→BSC $322,918.26 $59,776.53 22.3238 0.1296 461,162.21 
TAF→ETV→BSC $326,730.09 $3,811.83 22.3243 0.0005 7,876,809.40 
Absolutely Dominated Strategies (all referencing ETV→BSC) 
ETV→TDF→BSC $263,272.76 $11,101.19 22.1938 1.5494 7,164.99 
TAF→BSC $323,109.82 $70,938.25 21.9112 1.2668 56,000.07 
 
BSC, best supportive care; ETV, entecavir; HBeAg, hepatitis B envelope antigen; ICER, incremental cost-effectiveness ratio; 
QALY, quality-adjusted life year; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. 
 
compared with TDF→BSC (Table 2.2). Multitherapy strategies were more effective than monotherapy 
strategies (strategies without considering any subsequent therapy) since they can suppress the virus and 
maintain ALT levels for a longer period of time. Similar to the HBeAg-positive cohort, 
ETV→TDF→BSC almost generated the same amount of QALYs as TDF→ETV→BSC did at an 
additional cost. Strategies involving TAF were much more expensive than the others. 
ETV→TAF→BSC is therefore not a rational choice as its ICER compared with TDF→ETV→BSC 
($461,162.21/QALY) was far beyond the $100,000/QALY threshold. If we assume the willingness-to-
pay threshold to be either $50,000/QALY or $100,000/QALY, TDF→ETV→BSC is likely to be the 
most cost-effective treatment for HBeAg-negative CHB patients. 
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2.3.3 One-way Sensitivity Analyses 
For the HBeAg-positive cohort, the ten parameters that influence the ICER of TAF→ETV→BSC 
compared with TDF→ETV→BSC the most are shown in the tornado diagram (Figure A.1 (a)). The 
results of the base case analysis (at a willingness-to-pay threshold of $50,000/QALY) were generally 
reliable with the exception of the HBeAg seroconversion rates and viral suppression rates of the 
treatments. Since these rates determine the efficacy of a drug, changing any of them based on the 95% 
confidence intervals calculated from the published literature may alter the conclusions of this 
study.14,15,35 If the HBeAg seroconversion rate of TAF is raised to 12.8%, TAF→ETV→BSC would 
likely to be the most cost-effective treatment strategy. Furthermore, changes in many parameters, 
including the discount rate and the price of TAF, may result in the most cost-effective treatment (at a 
willingness-to-pay threshold of $100,000/QALY) being replaced from TAF→ETV→BSC to either 
TDF→ETV→BSC or ETV→TDF→BSC. On the other hand, the conclusion that TDF→ETV→BSC 
is more cost-effective than TDF→BSC is unlikely to be altered by changes in any of the parameters 
used by the model if we assume the willingness-to-pay threshold to be either $50,000/QALY or 
$100,000/QALY (Figure A.1 (b)). 
In the base case analysis, ETV→TDF→BSC almost produced the same amount of QALYs per 
person as TDF→ETV→BSC, but at an additional cost. The ICER of each of these two strategies 
compared with the other can be highly influenced by varying any of the parameters shown in Figure 
A.1 (c). In another sense, this figure may indicate that these two strategies are indistinguishable from 
each other. Since the differences between these two strategies are so small, changes in parameters are 
likely to cause a reversal of their relationship, and eventually, one of them will be absolutely dominated 
by the other. 
For the HBeAg-negative cohort, the ten parameters that influence the ICER of ETV→TAF→BSC 
compared with TDF→ETV→BSC the most are shown in Figure A.1 (d). The results of the base case 
analysis (at a willingness-to-pay threshold of $100,000/QALY) were only sensitive to the viral 
suppression rates of the treatments. If the viral suppression rate of TDF for HBeAg-negative patients is 
reduced to 85.7%, ETV→TAF→BSC would likely to be the most cost-effective treatment. On the other 
hand, the conclusion that TDF→BSC is more cost-effective than ETV→BSC is only sensitive to the 
viral suppression rate of ETV (Figure A.1 (e)). In addition, switching all the health state utilities from 
HUI3 scores to EQ-5D scores did not significantly affect the ICERs. 
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2.3.4 Probabilistic Sensitivity Analyses 
The cost-effectiveness of each strategy across a range of willingness-to-pay thresholds is shown in 
Figure 2.2. For the HBeAg-positive cohort, TDF→ETV→BSC had a 52.9% chance of being the 
optimal treatment strategy at a willingness-to-pay threshold of $50,000/QALY. The chances of 
TAF→ETV→BSC, ETV→TDF→BSC, and ETV→TAF→BSC were 28.7%, 14.1%, and 4.3%, 
respectively. The chances of the remaining three strategies were negligible. At a willingness-to-pay 
threshold of $100,000/QALY, the chances of TDF→ETV→BSC and ETV→TDF→BSC to be the 
optimal strategy shrunk to 42.8% and 9.4%, respectively. The chances of TAF→ETV→BSC and 
ETV→TAF→BSC rose to 39.6% and 8.1%, respectively. As a result, TDF→ETV→BSC has the 
highest chance of being the most cost-effective treatment for HBeAg-positive CHB infections even if 
randomness is allowed for most of the parameters used in the model. However, TAF→ETV→BSC still 
has a great potential to replace TDF→ETV→BSC and become the most cost-effective strategy. 
TDF→ETV→BSC also showed a clear advantage in the treatment of HBeAg-negative patients 
(Figure 2.2 (b)). It had a 66.5% chance of being the optimal treatment strategy at a willingness-to-pay 
threshold of $50,000/QALY. The chance of ETV→TDF→BSC was 28.8%, and the chances of the  
 
Figure 2.2 Probabilistic Sensitivity Analysis: Cost-effectiveness Acceptability Curve 




Figure 2.2 Continued 
(b) HBeAg-negative Cohort 
 
BSC, best supportive care; ETV, entecavir; HBeAg, hepatitis B envelope antigen; TAF, tenofovir alafenamide; TDF, tenofovir 
disoproxil fumarate. 
 
remaining five strategies were negligible. At a willingness-to-pay threshold of $100,000/QALY, the 
chances of TDF→ETV→BSC and ETV→TDF→BSC becoming the optimal strategy decreased to 
63.4% and 23.0%, respectively. The chance of ETV→TAF→BSC increased to 12.8%. Therefore, 
TDF→ETV→BSC has the highest chance of being the most cost-effective treatment for HBeAg-
negative CHB infections. However, the superiority of TDF→ETV→BSC compared with 
ETV→TAF→BSC may be weakened as the willingness-to-pay threshold reaches $200,000/QALY. 
2.4 Discussion 
We employed an STM to compare treatment strategies for CHB including ETV, TDF, and TAF, based 
on data from the available literature. The willingness-to-pay thresholds used by Canadian cost-
effectiveness studies ranged from $50,000/QALY to $100,000/QALY.19-21,38,67,68 At willingness-to-pay 
thresholds of $50,000/QALY to $100,000/QALY, TDF→ETV→BSC is relatively likely to be the most 
cost-effective treatment option for both HBeAg-positive and HBeAg-negative CHB patients, with 
ETV→TDF→BSC a potential alternative. At current prices, TAF-containing strategies were not found 
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to be cost-effective with $50,000 willingness-to-pay threshold. The results of the sensitivity analyses 
indicate that the model is robust, and uncertainty of model parameters is unlikely to alter the 
conclusions. 
Our analysis was built upon the first STM that includes treatment strategies involving TAF and 
incorporated efficacy outcomes of the treatments from the latest systematic review and network meta-
analysis.35 In addition, our study also developed the first STM that takes into account the impact of 
treatment-related SAEs on the costs and utilities. Although some cost-effectiveness analyses regarding 
CHB had considered treatment-related adverse events,24,69 the occurrence of adverse events was only 
treated as a sign of discontinuing treatment, without assessing its impact on costs and utilities as our 
analysis does. However, our study also has limitations. Long-term follow-up data regarding TAF is 
limited. Due to the nature of state-transition modeling, the model is unable to capture the impact of 
successful treatment on preventing viral transmission. The posted treatment price used by the model 
may also not be the same as the actual prices that public payers obtain through negotiations. 
Although strategies involving TAF are unlikely to be a rational choice for treating patients with CHB 
at this time, decision-makers may also be interested in the possibility of a TAF-containing strategy to 
be the most cost-effective strategy compared with the cheapest strategy considered in our study alone. 
To figure this out, an analysis was performed in a similar manner to the PSA, and the results showed 
that the chance of TAF→ETV→BSC becoming the optimal treatment for the HBeAg-positive cohort 
increased from 72.4% to 83.5% when the willingness-to-pay threshold ranged from $50,000/QALY to 
$100,000/QALY (Figure A.2 (a)). In addition, a threshold analysis was conducted and found that 
TAF→ETV→BSC will likely be the most cost-effective treatment option (at a willingness-to-pay 
threshold of $50,000/QALY) for HBeAg-positive and HBeAg-negative CHB patients if the drug price 
of TAF is reduced by more than 33.4% and 68.3%, respectively (Table A.2). 
This study assessed the predicted number of liver-related diseases and deaths, costs, QALYs, and 
ICERs of treatment strategies involving TAF as well as the other drugs for patients with HBeAg-
positive CHB or HBeAg-negative CHB, which would accelerate the decision-making process and 
provide a reference for future research. The WHO’s global hepatitis strategy calls for a 65% reduction 
in CHB deaths and a treatment rate of 80% in eligible CHB patients worldwide by 2030.27 Our analysis 






Although STM is the traditional way to assess the cost-effectiveness of a strategy, it cannot be used to 
simulate the prevalence and incidence of hepatitis B, which is a contagious disease, in a region. In 
contrast to STM which focuses on disease state transitions with each individual in isolation, ABM 
revolves around human activities. Instead of conceptualizing complex problems into several mutually 
exclusive states, ABMs describe things happening in the real world in a more natural way.30 
Agents simulated within an ABM can be identified by their characteristics such as age, sex, sexual 
identity, and immigrant status.30 They can recognize their situation and act on the basis of their 
characteristics.30 The interaction between agents is another key feature of this type of modeling.30 A 
complex contact network can be assigned to individuals indicating to whom they can transmit the 
disease and from whom they can be infected, which plays an important role in simulating the spread of 
a disease. A healthy individual may be infected at a point in time due to his or her characteristics and 
behavior. By adopting ABMs, the prevalence of CHB within a community over time can be predicted. 
However, none of the existing analyses regarding the HBV epidemic until now were built upon 
ABMs.19-24,38,69-72 
3.1 Methods 
To address these knowledge gaps, we developed an ABM to predict the impact of the treatment-as-
prevention strategies on HBV-related health outcomes,30 such as the prevalence of CHB, in Ontario 
over the next decade. A simulation conducted by the model began with the construction of a virtual 
society based on the real demographic data from Ontario. Then, the model randomly assigned contacts 
between agents and established a sexual network. As the simulated population grew with the addition 
of newborns and immigrants, HBV was also simulated to be transmitted from infected agents to healthy 
agents through the sexual network. We calibrated the ABM-simulated number of reported AHB 
infections with the historical reported cases in Ontario. After extensive calibration and validation 




Two treatment-as-prevention strategies were considered. The first strategy is TDF→ETV→BSC, the 
most cost-effective treatment for CHB infection found by the STM described in Chapter 2. The second 
one is TAF→ETV→BSC, which is the most clinically effective treatment strategy found in Chapter 2. 
The time horizon of each simulation performed by the ABM was 25 years (2006 to 2030) to predict 
how closely the long-term health outcomes resulting from the two treatment-as-prevention strategies 
can match the goals set by the WHO,27 with first 11 years (2006 to 2016) primarily for calibration and 
validation. Although TDF and ETV have been available in Canada since 2004 and 2006, respectively,18 
TAF was not approved for use in Canada until June 20, 2017. Therefore, we assumed that HBV-infected 
agents who are eligible for treatment had the same chance of receiving TDF→BSC, ETV→BSC, 
TDF→ETV→BSC, or ETV→TDF→BSC before 2017. The probability of receiving treatment for 
patients who know they are infected was assumed to rise from 0% to 40.7% from the beginning of 2006 
to the end of 2016,73 and this probability was assumed to remain unchanged from 2017 onwards. 
The last 14 years (2017 to 2030) of a simulation were primarily for prediction. After 2017, all HBV-
infected agents who are eligible for treatment were only likely to receive the same treatment strategy 
(one of the two treatment-as-prevention strategies considered). In order to highlight the impact of the 
treatment strategies applied during the prediction period (2017 to 2030) and to make a better 
comparison, we cleared the treatment history for all agents before the start of the prediction period. 
3.1.2 Model Structure 
In order to achieve the spread of disease due to human interactions and to predict the extent to which 
the long-term health outcomes of CHB treatment strategies match the WHO’s goals,27 an ABM was 
employed to simulate population dynamics and HBV transmission in Ontario from 2006 to 2030.30 The 
model consisted of agents, contact networks among the agents, HBV vaccination, treatment of CHB, 
and the natural history of HBV based on the STM described in Chapter 2. Unlike the cohorts considered 
by the STM, the population targeted by the ABM was all people living in Ontario, including both HBV-
infected patients and healthy people. 
3.1.2.1 Characteristics of the Simulated Agents 
A large number of individuals was simulated to represent the 12.2 million population of Ontario in 
2006.74 In order to alleviate the computational intensity, the scaling ratio between the simulated agents 
and the target population was set to 1:10. We probabilistically assigned characteristics, such as age, 
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gender, residential address, immigrant status, place of birth, and health status, to the simulated 
population based on the 2006 census of Canada and the published literature (Figure 3.1).3,4,73,74 For the 
sake of simplicity, we assumed that everyone in this virtual society is heterosexual. The residential 
address of the agents was recorded as the forward sortation areas (FSAs) in which they live, and Ontario 
consisted of 509 FSAs in 2006.74 
The health status of an agent was subdivided into vaccination status, infection status, age at infection, 
HBV viral load, awareness of being infected, and the disease progression state (which can be immune 
tolerance (IT), AHB, or any health states considered in the STM described in Chapter 2) he or she is 
currently in (Figure 3.1). Infants and young children have a much higher chance of developing CHB 
from AHB compared with adults, and adults in the AHB state are more likely to develop symptoms 
than infants and young children.10 Patients who have developed AHB symptoms were assumed to 
automatically become aware that they are infected with HBV. Agents also followed the natural laws of 
aging and death. Everyone in the simulated population had a certain probability of death due to reasons 
unrelated to HBV, and this probability was based on the life tables provided by Statistics Canada.32 We 
assumed that chronically infected agents will not leave the IT state until they reach the age of 12.2,7 
Not everyone infected with HBV knows that they are infected. According to a recently published 
modeling study, only 58% of HBV-infected patients in Canada were diagnosed.73 In the ABM, patients 
who know they are infected were eligible for treatment, and antiviral treatments were only applied to 
patients in the CHB or CC states according to the AASLD guidelines.17 On the other hand, 
approximately 29% of the total population of Canada has immunity induced by hepatitis B vaccination.3 
As the age range narrows to 14 to 19, this ratio can be raised to 72.6% based on data provided by the 
Canadian Health Measures Survey.3 Since Ontario has introduced a routine HBV vaccination program 
for seventh-grade students,9 we assumed that 87.5% of the agents will be vaccinated at the age of 12.10 
We also assumed that a certain percentage of agents who do not know whether they are infected will 
voluntarily screen for HBV and a certain percentage of unvaccinated healthy agents will voluntarily 
receive hepatitis B vaccination every year.75 How these two percentages were estimated is explained in 
Section 3.1.5. 
3.1.2.2 Immigrants and Newborns 
Immigration demographic data were obtained from Statistics Canada.4,76 Individuals classified as 
immigrants included those who are, or who have ever been, landed immigrants or permanent residents.4 
Immigrants consisted of 24.0% of the total Ontario population in early 2006,4 and we assumed that all 
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Figure 3.1 Agent-related Section of the Agent-based Model 
 
AHB, acute hepatitis B; CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompensated cirrhosis; HBeAg-, 
hepatitis B envelope antigen-negative; HBeAg+, hepatitis B envelope antigen-positive; HBsAg, hepatitis B surface antigen; 




immigrants were born outside of Canada. Since HBV-related data, such as the prevalence of HBV, in 
many countries around the world are unknown or unavailable, the birthplace of all agents simulated 
was categorized into 19 regions:4,73
1) Canada; 
2) North America, excluding Canada; 
3) Central America; 
4) Caribbean and Bermuda; 
5) South America; 
6) Western Europe; 
7) Eastern Europe; 
8) Northern Europe; 
9) Southern Europe; 
10) Western Africa; 
11) Eastern Africa; 
12) Northern Africa; 
13) Central Africa; 
14) Southern Africa; 
15) West Central Asia and the Middle East; 
16) Eastern Asia; 
17) Southeast Asia; 
18) Southern Asia; and 
19) Oceania.
We assumed that people from the same region, regardless of the country in which they were born, have 
similar probabilities of being infected and diagnosed with HBV. Due to the lack of data, the 
probabilities of being infected and diagnosed with HBV in Southern Africa were assumed to be the 
same as the world averages.73 
Newborns and immigrants were added to the virtual community every week based on real Canadian 
data.76,77 Immigrants were assumed to be more inclined to migrate to more populated regions. The 
annual number of newborns and immigrants was assumed to remain unchanged from 2017 onwards. 
The probability that a Canadian-born agent was infected before 2006 was assumed to be 0.4%.3 The 
probability of a foreign-born agent being infected before 2006 or before immigrating to Canada was 
considered to be correlated with his or her birthplace. In order to match the overall HBV prevalence in 
Ontario in 2016 with the prevalence of HBV in Canada (0.6%) stated in a recently published article,73 
we calculated and assumed that immigrants are relatively economically self-sufficient and well 
educated so that they are 60% less likely to be infected with HBV before immigrating to Canada than 
the overall population of their home country, based on previous immigration data.4,73 We also assumed 
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that the chance of immigrants receiving HBV vaccination before immigrating to Canada follows the 
same pattern as the vaccination rate of those born in Canada.3 
3.1.2.3 Contact Networks 
In the ABM, agents behaved and interacted with each other based on their characteristics. Age-
appropriate agents formed a sexual network, which was assumed to be a scale-free network.78,79 The 
probability that a randomly selected agent in the network has 𝑘 sexual partners at the same time can be 
determined by 
𝑃(𝑘) = {
 𝑐𝑘−𝛾     , 𝑖𝑓 𝑘 > 0
 𝑝0         , 𝑖𝑓 𝑘 = 0
 
where 𝑐 (𝑐 ≥ 0) is a normalizing constant,78,79 𝛾 (𝛾 > 1) is a constant that controls the shape of the 
distribution,79 and 𝑝0 (0 ≤ 𝑝0 ≤ 1) is a constant as defined by the formula.
78 The maximum number of 
partners an agent can manage was assumed to be 200,78 and the model did not allow agents who are 
younger than 15 or older than 79 to make a sexual partner or to acquire or transmit HBV through sexual 
contacts.4,32 We assumed that everyone has an expected number of partners that he or she can manage, 
and that number has been determined at the time he or she was born. Sexual relationships can be either 
casual or steady with a certain probability.4,78 Steady relationships were assumed to be similar to 
marriage or living common-law. Only one steady relationship was allowed per agent.78 
The model probabilistically pairs up random male and female agents every week if the total number 
of relationships in the sexual network does not exceed the expected maximum number. The probability 






















     , 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                 
 
where 𝑃𝑙𝑜𝑜𝑘 is the willingness of an agent to find a sexual partner,
79 𝑃𝑓𝑜𝑟𝑚 is the possibility of forming 
a relationship between two agents with a given age difference, 𝛽 (0 < 𝛽 ≤ 1) is a constant that controls 
the shape of the distribution, 𝑀𝑁𝑃 (𝑀𝑁𝑃 = 200) denotes the maximum number of partners that an 
agent can manage,78 𝐸𝑁𝑃 (𝐸𝑁𝑃 ∈ {1,2,… ,𝑀𝑁𝑃}) represents the expected number of partners that an 
agent can manage, 𝑑𝑖𝑠𝑡𝐹,𝑀 is the distance between the residential address of the two agents, and 𝑑𝑖𝑠𝑡𝑜𝑝𝑡 
denotes the maximum optimum distance for sexual relationships.79 For agents with a steady partner, 
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the willingness to find additional partners was assumed to be lower than those without any steady 
partners. In determining ages of partners, a study found that for those married in England and Wales in 
2001, the average age of the husband was 2.6 years older than his wife.80 We assumed that the age 
difference between couples in Ontario is similar to that in England and Wales. As a result, sexual 
relationships between men and women in the model were more likely to be formed if their willingness 
to find a sexual partner is high, they have similar ages, they live close to each other, or the total number 
of partners they can manage is high. 
The spread of HBV in the sexual network may occur when an infected agent had sexual contact with 
an uninfected agent, and the probability of disease transmission per sexual intercourse (𝑃𝑡𝑟𝑎𝑛𝑠) depends 
on the sex of the participants,81 the health and treatment status of the infected agent, and whether 
condoms were used during the sexual activity. The probability of 𝐴 (a healthy agent who has a steady 
relationship with an HBV-infected agent, 𝑆 , and casual relationships with HBV-infected agents, 
𝐶1, 𝐶2, … , 𝐶𝑚) being infected with HBV over a period of time can be calculated by 
𝑃(𝐴) = 1 − (1 − 𝑃𝑡𝑟𝑎𝑛𝑠(𝑆, 𝐴))
𝑁𝑆





where 𝑁 is the number of sexual activities conducted by the agent, 𝐴, and a given agent during the 
period. The more partners a person has, the less often he or she has sex with each partner. We assumed 
that the total number of sexual activities of an agent over a period of time follows a Poisson distribution, 
and the number of sexual activities assigned by an agent to his or her steady partner and casual partners 
may be very different. The ratio of the number of sexual activities assigned by an agent, 𝐴, to a casual 




where 𝑘 (𝑘 ∈ {2,3, … ,200})  is the total number of partners the agent, 𝐴 , has and 𝛼 (𝛼 ≥ 0)  is a 
constant that controls the shape of the distribution. Agents who are newly infected with HBV started 
with AHB. Once their disease turned chronic, they will follow the path of disease progression defined 
by the STM described in Chapter 2. 
The duration of the sexual relationships was simulated by an exponential distribution. A steady 
relationship usually lasts longer than a causal relationship.79,82 Once a sexual relationship between a 
male and a female reached its predetermined time limit, the relationship ends. In addition, individuals 
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in the ABM had limited knowledge of themselves and the people around them. No one had the ability 
to investigate and exploit the underlying trends (such as the prevalence of HBV) that exist in the virtual 
society. 
3.1.3 Implementation and Additional Assumptions 
By combining multi-agent systems and complex networks, the ABM was developed using C++ 
programming language and object-oriented programming concepts.83 In order to improve runtime 
efficiency of the main computer program containing the model, a number of model inputs were pre-
computed outside the main program and converted to a program-readable format using the Visual Basic 
for Applications programming language. The time horizon of the model was 25 years (2006 to 2030). 
Each year was divided into 52 cycles, and the length of each cycle was defined as one week. 
Based on immigration data obtained from the 2016 Canadian Census,4 we assumed that Canada has 
three immigration periods (before 2006, 2006 to 2010, and 2011 to 2016), each with a unique structure 
of immigrant birthplace. Changes in immigration period led to variations in the prevalence and 
diagnostic rate of HBV in the 18 immigrant-sourced regions.4,73 We assumed that the structure of 
immigrant birthplace will remain unchanged after 2016. 
One of the difficulties affecting the feasibility of the program design is that it does not allow the 
establishment date of the relationship between two healthy agents to be determined. Thus, when a 
relationship should be broken is unknown to the program. The problem was solved by the memoryless 
property of the exponential distribution. Since the duration of the sexual relationships was assumed to 
follow an exponential distribution, the probability that a relationship ends in a cycle given that the 
relationship has lasted for an unknown period of time, 𝑡, can be expressed as 
𝑃(𝑋 < 𝑡 + 𝑠 | 𝑋 > 𝑡) = 1 − 𝑃(𝑋 > 𝑡 + 𝑠 | 𝑋 > 𝑡) = 1 − 𝑃(𝑋 > 𝑠) = 𝑃(𝑋 < 𝑠) 
where 𝑋 is the duration of a relationship, 𝑋 follows an exponential distribution, and 𝑠 is the length of a 
cycle. Thus, the program does not need to care about how long a relationship has been formed during 
simulations. 
We assumed that 58.9% of the uninfected individuals between the ages of 15 and 79 have a steady 
partner in the model. This number was calculated by averaging the proportions of Ontarians (15 to 79 
years old) who were married or living common-law in 2006, 2011 and 2016.4 We also assumed that 
whether an agent has a steady partner is uncorrelated with his or her HBV infection status. 
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3.1.4 Input Data 
The parameters adopted by the ABM regarding the natural history of CHB and CHB treatments were 
identical to those used in the STM and were collected from the same sources stated in Chapter 2. The 
parameters regarding AHB were obtained from the Public Health Agency of Canada (Table 3.1).10 
Population-related parameters, including demographic characteristics, annual number of immigrants 
and newborns, and fertility rates were obtained from Statistics Canada.4,74,76,77,84,85 HBV screening and 
vaccination rates, prevalence and diagnostic rates of HBV in various countries, and treatment rates for 
patients diagnosed with HBV were collected from the Public Health Agency of Canada and the 
published literature.3,9,10,73 
3.1.5 Calibration 
Since certain parameters, especially those related to sexual networks and sexual behavior, are 
unavailable and unlikely to be accurately determined in the real world, we used a calibration process to 
estimate their values. The goal of this process was to match the reported number of AHB in Ontario 
from 2006 to 2014 produced by the ABM with the incidence of AHB reported in the real world.86,87 
The goodness of fit (GOF) of the model outputs to the calibration targets was assessed by the log-
likelihood of the real-world observations. The calibration process was implemented primarily using 
O’Neill’s version of the Nelder-Mead algorithm since it can fulfill the goal by conducting a relatively 
small number of simulations.88,89 At the beginning of the process, a small set of value sets was selected 
from the uncertain parameter space based on a randomly generated set of uncertain parameter values. 
The calibrated range for each uncertain parameter was determined based on assumptions or articles 
related to the parameter.75,79,81 At each iteration, the value set (within the set of uncertain parameter 
value sets) that produces the lowest GOF was replaced by a better set of values according to the 
algorithm. The calibration process ends when the values of GOF generated by the set of uncertain 
parameter value sets reach a steady equilibrium. This process was repeated several times to maximize 
the GOF that can be produced and avoid local minimal solutions. The final estimates of the uncertain 
parameters were the set of values that can produce an HBV epidemic that closely matched the observed 




Table 3.1 Additional Model Inputs for the Agent-based Model 
AHB-related Probabilities 
Parameter Baseline Low High Source 
Probability of Developing AHB Symptoms (infants) 0.05 0.0375† 0.0625‡ 10 
Probability of Developing AHB Symptoms (children aged 1 to 5 years) 0.1 0.075† 0.125‡ 10 
Probability of Developing AHB Symptoms (adolescents and adults) 0.6 0.5 0.7 10 
Probability of AHB to HBeAg+ CHB (infants) 0.9 0.675† 1‡ 10 
Probability of AHB to HBeAg+ CHB (children aged 1 to 5 years) 0.375 0.25 0.5 10 
Probability of AHB to HBeAg+ CHB (adolescents) 0.075 0.05 0.1 10 
Probability of AHB to HBeAg+ CHB (adults) 0.03 0.01 0.05 10 
HBV Screening and Vaccination Related Probabilities 
Parameter Baseline Low High Source 
Probability of Being Vaccinated at Age 12 Due to a School-based Vaccination Program 0.875 0.78 0.97 9, 10 
Probability of Being Protected by Vaccines (people aged 12 to 13) 0.875 0.78 0.97 Assume same as the school-based vaccination program 
Probability of Being Protected by Vaccines (people aged 14 to 19) 0.726 0.5445† 0.9075‡ 3 
Probability of Being Protected by Vaccines (people aged 20 to 24) 0.666 0.4995† 0.8325‡ 3 
Probability of Being Protected by Vaccines (people aged 25 to 29) 0.520 0.3900† 0.6500‡ 3 
Probability of Being Protected by Vaccines (people aged 30 to 34) 0.295 0.2213† 0.3688‡ 3 
Probability of Being Protected by Vaccines (people aged 35 to 39) 0.243 0.1823† 0.3038‡ 3 
Probability of Being Protected by Vaccines (people aged 40 to 49) 0.165 0.1238† 0.2063‡ 3 
Probability of Being Protected by Vaccines (people aged 50 to 59) 0.155 0.1163† 0.1938‡ 3 
Probability of Being Protected by Vaccines (people aged 60 to 69) 0.131 0.0983† 0.1638‡ 3 
Probability of Being Protected by Vaccines (people aged 70 to 79) 0.065 0.0488† 0.0813‡ 3 
Annual Probability of Voluntary Screening 0.0136 0 0.02 75, Calibration 





Table 3.1 Continued 
Other Parameters 
Parameter Baseline Low High Source 
Number of Cycles per Year 52   Assumption 
Initial Population Size 12,160,282   74 
Population Scaling Ratio 0.1   Assumption 
Relative Risk of Being HBV Infected for Immigrants vs General Population 0.4 0.3† 0.5‡ 3, 4, 73 
Minimum Age Allowed in the Sexual Network 15   4 
Maximum Age Allowed in the Sexual Network 79   4, 32 
Maximum Number of Sexual Partners Allowed per Person 200   78 
Proportion of People in the Sexual Network Having a Steady Relationship 0.5888 0.4416† 0.7360‡ 4 
Mean Age Difference (male age minus female age) for a Couple 2.6   80 
Standard Deviation of a Couple's Age Difference (male age minus female age) 6.3   80 
Shape of the Distribution of Pairing Success Rate (beta) 0.4 0.3† 0.5‡ Assumption 
Probability of HBV Transmission per Unprotected Sexual Intercourse (female to male) 0.0004 0.0003 0.0009 81, Calibration 
Probability of HBV Transmission per Unprotected Sexual Intercourse (male to female) 0.0003 0.00018 0.0015 81, Calibration 
Relative Risk of HBV Transmission for Infected People with Viral Suppression vs No Viral Suppression 0.1797 0.06 0.18 Calibration 
 
†75% of its baseline value; ‡125% of its baseline value. 





First, we validated the section of the ABM representing the natural history of hepatitis B. Two 
simulations on 1,000,000 individuals with the same characteristics as the two cohorts considered by the 
previously developed STM were performed, respectively. The lifetime health outcomes of the 
simulated population were compared with the results generated by the STM. Second, we determined 
how accurately the ABM (incorporating Ontario demographic data and calibrated uncertain parameter 
values) can estimate the reported incidence of AHB in Ontario in 2015 and 2016 and the population of 
Ontario from the end of 2006 to the end of 2018 compared with the real-world observations.86,87,90 To 
eliminate the impact of randomness on the model outcomes, the results were the average of the results 
produced by 1,000 simulations using 1,000 randomly generated random number generator seeds. 
3.1.7 Outcomes 
The ABM predicted the actual prevalence of CHB, the reported incidence of AHB, and the actual 
incidence of CHB, DC, HCC, and liver-related death in Ontario from 2017 to 2030 for each of the 
treatment-as-prevention strategies considered. We performed 1,000 simulations for each strategy using 
the same set of random number generator seeds used to validate the model. The final results were the 
average of the results produced by the random number generator seeds. 
3.1.8 Sensitivity Analyses 
As recommended in a modeling guideline,91 PSA, a type of sensitivity analysis that causes a large 
number of parameter changes, may be inappropriate for ABMs. The correlation between the parameters 
used by an ABM needs to be maintained to ensure that the model is a reasonable fit to the observed 
data,91 which is difficult for PSA. Instead, we separately determined the impact of the following changes 
in the parameter regions on the prediction results based on our key assumptions: 
1) increasing and decreasing the number of newborns by 25% after 2016; 
2) increasing and decreasing the number of immigrants by 25% after 2016; 
3) increasing and decreasing the HBV vaccination rate in immigrants aged 14 to 79 by 25% after 
2016; 
4) increasing and decreasing the HBV prevalence rates in immigrant-sourced regions after 2016 




5) increasing and decreasing the HBV diagnostic rate in immigrants by 25% after 2016; 
6) increasing and decreasing the treatment rate in HBV-infected patients who are eligible for 
treatment by 25% after 2016; and 
7) increasing and decreasing the efficacy of TAF, TDF, and ETV after 2016 based on the credible 
intervals stated in Table 2.1. 
All sensitivity analyses were conducted in a similar manner to the method described in Section 3.1.7. 
3.2 Results 
3.2.1 Validation 
The lifetime health outcomes of HBeAg-positive and HBeAg-negative CHB patients treated with the 
corresponding treatment strategies estimated by the ABM and the STM described in Chapter 2 are 
shown in Table 3.2. All predictions generated by the two models closely match each other, including 
the lifetime probability of DC for patients initiated with HBeAg-positive non-cirrhotic CHB being 
32.9% and 31.8% (assuming they had the same chance to receive any of the seven treatment strategies 
considered in Chapter 2) in the ABM and STM, respectively, and the lifetime probability of liver-
related death being 41.8% and 41.6% in the ABM and STM, respectively. This indicates that the section 
of the ABM representing the natural history of hepatitis B is consistent with that of the STM. 
3.2.2 Calibration 
The optimal values of the 17 uncertain parameters found during the calibration process are shown in 
Table 3.3. The reported number of AHB cases from 2006 to 2016 observed in the real world and the 
one simulated by the ABM using this set of parameter values are shown in Figure 3.2.86,87 The two 
trends are very similar to each other. Although the calibration process only attempted to estimate the 
uncertain parameter values that can produce a set of values that match the reported incidence of AHB 
in Ontario from 2006 to 2014 observed in the real world, the model-generated AHB incidence from 
2015 to 2016 is also very close to the observed data. The GOF between the two curves was 3.41, and 




Table 3.2 Health Outcomes of 1,000 Patients Initiated with Non-cirrhotic Chronic Hepatitis B 
(a) HBeAg-positive Cohort 
Strategy Model 
DC 
(Number Prevented If Using 
TDF→ETV→BSC) 
HCC 
(Number Prevented If Using 
TDF→ETV→BSC) 
Liver-related Death 
(Number Prevented If Using 
TDF→ETV→BSC) 
Liver-related Death Caused by DC 
(Number Prevented If Using 
TDF→ETV→BSC) 
Liver-related Death Caused by HCC 
(Number Prevented If Using 
TDF→ETV→BSC) 
BSC 
STM 391 (84)   281 (60)   520 (120)   244 (56)   212 (47)   
ABM 396 (78)   287 (56)   512 (110)   231 (49)   195 (39)   
TAF→BSC 
STM 323 (16)   231 (10)   423 (23)   200 (12)   173 (8)   
ABM 334 (16)   243 (12)   426 (24)   192 (10)   164 (8)   
TDF→BSC 
STM 332 (25)   237 (16)   434 (34)   205 (17)   178 (13)   
ABM 341 (23)   249 (18)   436 (34)   197 (15)   168 (12)   
ETV→BSC 
STM 363 (56)   260 (39)   478 (78)   225 (37)   196 (31)   
ABM 371 (53)   268 (37)   474 (72)   214 (32)   182 (26)   
TAF→ETV→BSC 
STM 299 (-8)   215 (-6)   389 (-11)   183 (-5)   161 (-4)   
ABM 312 (-6)   227 (-4)   394 (-8)   178 (-4)   153 (-3)   
TDF→ETV→BSC 
STM 307     221     400     188     165     
ABM 318     231     402     182     156     
ETV→TAF→BSC 
STM 298 (-9)   215 (-6)   389 (-11)   183 (-5)   161 (-4)   
ABM 310 (-8)   226 (-5)   393 (-9)   177 (-5)   153 (-3)   
ETV→TDF→BSC 
STM 306 (-1)  220 (-1)  399 (-1)  188 (0)  164 (-1)  





Table 3.2 Continued 
(b) HBeAg-negative Cohort 
Strategy Model 
DC 
(Number Prevented If Using 
TDF→ETV→BSC) 
HCC 
(Number Prevented If Using 
TDF→ETV→BSC) 
Liver-related Death 
(Number Prevented If Using 
TDF→ETV→BSC) 
Liver-related Death Caused by DC 
(Number Prevented If Using 
TDF→ETV→BSC) 
Liver-related Death Caused by HCC 
(Number Prevented If Using 
TDF→ETV→BSC) 
BSC 
STM 352 (98)   246 (76)   441 (144)   212 (66)   182 (60)   
ABM 366 (98)   257 (77)   443 (140)   206 (61)   172 (54)   
TAF→BSC 
STM 265 (11)   178 (8)   314 (17)   154 (8)   129 (7)   
ABM 279 (11)   189 (9)   320 (17)   152 (7)   124 (6)   
TDF→BSC 
STM 276 (22)   187 (17)   329 (32)   160 (14)   136 (14)   
ABM 289 (21)   198 (18)   334 (31)   158 (13)   130 (12)   
ETV→BSC 
STM 329 (75)   229 (59)   406 (109)   196 (50)   169 (47)   
ABM 344 (76)   239 (59)   408 (105)   191 (46)   158 (40)   
TAF→ETV→BSC 
STM 244 (-10)   162 (-8)   284 (-13)   140 (-6)   117 (-5)   
ABM 257 (-11)   173 (-7)   291 (-12)   139 (-6)   113 (-5)   
TDF→ETV→BSC 
STM 254     170     297     146     122     
ABM 268     180     303     145     118     
ETV→TAF→BSC 
STM 244 (-10)   162 (-8)   284 (-13)   140 (-6)   117 (-5)   
ABM 258 (-10)   172 (-8)   290 (-13)   139 (-6)   113 (-5)   
ETV→TDF→BSC 
STM 254 (0)  170 (0)  297 (0)  146 (0)  122 (0)  
ABM 267 (-1)   181 (1)   303 (0)   144 (-1)   118 (0)   
 
ABM, agent-based model; BSC, best supportive care; DC, decompensated cirrhosis; ETV, entecavir; HBeAg, hepatitis B envelope antigen; HCC, hepatocellular carcinoma; STM, 




Table 3.3 Calibrated Parameters 
Parameter Calibrated Range Optimal Value 
Probability of a Female Having No Sexual Partner 0.075–0.125 0.1028 
Probability of a Male Having No Sexual Partner 0.075–0.125 0.0784 
Sexual Network Scale Free Gamma (female) 1.8–4.2 4.1700 
Sexual Network Scale Free Gamma (male) 1.8–4.2 3.3511 
Relative Risk of Looking for Sexual Partners for People with a Steady Partner vs No Steady Partner 0.15–0.45 0.2586 
Maximum Optimum Distance for Sexual Relationships (km) 50–200 147.1690 
Mean Steady Relationship Duration (year) 8–24 9.2863 
Mean Casual Relationship Duration (year) 0.5–1.5 0.9782 
Mean Number of Sexual Contacts per Person per Year 80–300 91.9641 
Shape of the Distribution of Assigning Sexual Contacts (alpha) 0.5–2 1.8645 
Probability of HBV Transmission per Unprotected Sexual Intercourse (female to male) 0.0003–0.0009 0.0004 
Probability of HBV Transmission per Unprotected Sexual Intercourse (male to female) 0.00018–0.0015 0.0003 
Relative Risk of HBV Transmission for Infected People with Viral Suppression vs No Viral Suppression 0.06–0.18 0.1797 
Condom Use Rate for Steady Relationships 0.2–0.6 0.5256 
Condom Use Rate for Casual Relationships 0.525–0.875 0.8478 
Annual Probability of Voluntary Screening 0–0.02 0.0136 
Annual Probability of Voluntary Vaccination 0–0.02 0.0185 
 




Figure 3.2 Reported Incidence of Acute Hepatitis B 
 
 
Although the model took into account the actual population of Ontario in 2006 and the actual annual 
number of newborns and immigrants,74,76,77 the annual number of deaths simulated by the model mainly 
depended on the age and health status of the agents. This means that the simulated population size 
cannot be guaranteed to be the same as the actual population size of Ontario after 2006. However, the 
population of Ontario from the end of 2006 to the end of 2018 estimated by the model closely matched 
with the observed data,90 as shown in Figure 3.3. As a result, the model incorporating the parameter 
values found through the calibration process is credible. 
The calibration process found that the probability of a randomly selected male and a randomly 
selected female having no sexual partner in the model was 7.8% and 10.3%, respectively (Figure 3.4). 
The sexual network scale free gammas for males and females were found to be 3.4 and 4.2, respectively. 
This implies that 80.5% of the males and 83.7% of the females in the model had only one partner, and 





Figure 3.3 Population of Ontario 
 
 





Based on the calibrated ABM as described in Section 3.2.2, we projected the outcomes as mentioned 
in Section 3.1.7. The reported incidence of AHB and the actual incidence of CHB in Ontario from 2017 
to 2030 predicted by the model are shown in Figure 3.5 and Figure 3.6. However, these incidence rates 
resulting from TDF→ETV→BSC and TAF→ETV→BSC were not significantly different from each 
other. For both of the strategies, the incidence of AHB and CHB decreased by roughly 48.9% and 
52.2% from 2017 to 2030, respectively. 
The ABM predicted that the actual prevalence of CHB in Ontario resulting from either 
TDF→ETV→BSC or TAF→ETV→BSC would decrease by 11.5% from 2017 to 2030, reaching 
0.50% (Figure 3.7). Throughout the predicted years, the prevalence of CHB declined almost linearly, 
dropping by 5 per 100,000 population every year. Similar to the reported incidence of AHB, the two 
curves shown in Figure 3.7 almost overlapped each other, indicating that receiving TDF→ETV→BSC 
or TAF→ETV→BSC does not show a significant difference in the prevalence of CHB. 
 
Figure 3.5 Reported Incidence of Acute Hepatitis B 
 




Figure 3.6 Actual Incidence of Chronic Hepatitis B 
 
BSC, best supportive care; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. 
 
Figure 3.7 Actual Prevalence of Chronic Hepatitis B 
 
BSC, best supportive care; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. 
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Receiving any of the two treatment-as-prevention strategies considered in this study did not show 
clear differences in the actual incidence of DC, HCC, and liver-related death either (Figure 3.8, Figure 
3.9, and Figure 3.10). The model predicted that the incidence of DC in Ontario resulting from 
TDF→ETV→BSC and TAF→ETV→BSC decreased by 9.9% and 9.8% from 2017 to 2030, 
respectively. For both of the strategies, the incidence of HCC increased from 2017 to 2020 and then 
began to decline. In 2030, the incidence rates resulting from TDF→ETV→BSC and 
TAF→ETV→BSC decreased by 1.8% and 1.9% compared with those in 2017, respectively. The 
incidence of liver-related death was generally increasing throughout the predicted years but had tended 
to decline after 2024. Overall, the incidence of liver-related death resulting from the two strategies 
increased by roughly 12.3% on average from 2017 to 2030. 
 
Figure 3.8 Actual Incidence of Decompensated Cirrhosis 
 







Figure 3.9 Actual Incidence of Hepatocellular Carcinoma 
 
BSC, best supportive care; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. 
 
Figure 3.10 Actual Incidence of Liver-related Death 
 
BSC, best supportive care; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. 
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3.2.4 Sensitivity Analyses 
By incorporating the ABM with the optimal set of parameter values found through the calibration 
process, the effect of parameter changes mentioned in Section 3.1.8 on HBV-related health outcomes 
was projected. Immigrants may come from regions where the prevalence of HBV is higher than that in 
Canada. By increasing the number of immigrants after 2016 by 25%, the percentage of decline in the 
actual prevalence of CHB resulting from either TDF→ETV→BSC or TAF→ETV→BSC from 2017 
to 2030 decreased to 7.0% compared with the prediction results (11.5%) described in the previous 
section (Figure 3.11 (a)). By decreasing the number of immigrants after 2016 by 25%, the percentage 
of decline in actual CHB prevalence from 2017 to 2030 increased to 16.4%. On the other hand, the 
increase and decrease in the number of immigrants after 2016 led to a drop in the reported incidence of 
AHB from 2017 to 2030 by about 46.1% and 53.1%, respectively (Figure 3.11 (b)). Since the impact 
of interventions on liver-related death takes a long time to be observed, changes in the number of 
immigrants have no clear effect on the actual incidence of liver-related death as shown in Figure 3.11 
(c). Although the incidence rates from 2017 to 2026 resulting from increasing the number of immigrants 
were generally lower than that from decreasing the number of immigrants, this may be due to a dilution 
effect brought on by the growth of the total population. Contrary to decreasing the number of 
immigrants, increasing the total number of immigrants implies an increase in the number of HBV- 
 
Figure 3.11 Impact of Changes in the Number of Immigrants on HBV-related Health Outcomes 




Figure 3.11 Continued 
(b) Reported Incidence of Acute Hepatitis B 
 
(c) Actual Incidence of Liver-related Death 
 
BSC, best supportive care; ETV, entecavir; HBV, hepatitis B virus; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil 
fumarate. 
 
infected immigrants, which may be the reason why it did not result in a significant downtrend in the 
incidence of liver-related death as the year approached 2030. 
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Similar to changes in the number of immigrants, increasing the HBV prevalence rates in immigrant-
sourced regions after 2016 caused the percentage of decline in the actual prevalence of CHB and the 
reported incidence of AHB from 2017 to 2030 to fall to 7.0% and 46.2%, respectively (Figure B.1 (a) 
and Figure B.1 (b)). Decreasing the prevalence of HBV in immigrant-sourced regions after 2016 caused 
the percentage of decline in the prevalence of CHB and the incidence of AHB to rise to 15.8% and 
52.0%, respectively. As changes in the HBV prevalence rates in immigrant-sourced regions only affect 
the proportion of HBV-infected people in immigrants without directly changing the size of the 
population, the increase and decrease in these rates after 2016 led to an increase in the actual incidence 
of liver-related death from 2017 to 2030 by about 14.5% and 9.5%, respectively (Figure B.1 (c)). 
Since the ABM did not consider perinatal infections, all newborns were considered non-infected with 
HBV when they were added to the virtual society created by the model. By increasing the number of 
newborns after 2016 by 25%, the percentage of decline in the actual prevalence of CHB from 2017 to 
2030 increased to 14.0%, regardless of the treatment-as-prevention strategies considered (Figure B.2 
(a)). By decreasing the number of newborns after 2016 by 25%, the percentage of decline was reduced 
to 8.8%, while the reported incidence of AHB resulting from increasing the number of newborns was 
generally lower than that resulting from decreasing the number of newborns as shown in Figure B.2 
(b). The increase and decrease in the number of newborns after 2016 also led to an increase in the actual 
incidence of liver-related death in Ontario from 2017 to 2030 by approximately 8.7% and 15.9%, 
respectively (Figure B.2 (c)). 
Changes in the remaining four parameter regions described in Section 3.1.8 did not have a significant 
impact on the HBV-related health outcomes (Figure B.3, Figure B.4, Figure B.5, and Figure B.6). 
Excluding the HBV vaccination rate in immigrants, all of them are directly related to the treatment of 
CHB. In addition, all changes considered in the sensitivity analyses failed to significantly differentiate 
the effect of the two treatment-as-prevention strategies on the health outcomes. 
3.3 Discussion 
The ABM predicted an 11.5% decline in the actual prevalence of CHB in Ontario from 2017 to 2030 
if all CHB patients eligible and ready for treatment begin to receive TDF→ETV→BSC or 
TAF→ETV→BSC after 2016. Although TAF is a novel prodrug of TDF approved for the treatment of 
CHB in recent years, TAF→ETV→BSC was not found to significantly differ from TDF→ETV→BSC 
in reducing the prevalence of CHB in this study. WHO’s global hepatitis strategy calls for a 90% 
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reduction in new CHB cases, and a 65% reduction in CHB deaths worldwide by 2030.27 Our model 
predicted that the reported incidence of AHB and the number of new CHB cases in Ontario would only 
drop by 48.9% and 52.2%, respectively. This is far below the target set by the WHO. Conversely, the 
actual number of liver-related death is expected to increase by approximately 12.3% from 2017 to 2030, 
regardless of the treatment-as-prevention strategies considered. HBV-related health outcomes were 
found to be sensitive to the number of immigrants and newborns, and the prevalence of HBV in the 
immigrant-sourced regions. Furthermore, the conclusion that TDF→ETV→BSC and 
TAF→ETV→BSC have no significant difference in reducing the prevalence and incidence of HBV-
related health outcomes is unlikely to be altered due to changes in any of the seven parameter regions 
considered in the sensitivity analyses. 
Our analysis was built upon the first ABM associated with hepatitis B transmission. This model 
adequately solved the limitation of STMs related to their inability to simulate the impact of strategies 
on the spread of HBV. The ABM we developed can provide evidence on whether long-term HBV 
elimination goals can be achieved by treatment-as-prevention strategies. However, our study also has 
limitations. The model cannot simulate the repartition of the FSAs in Ontario and the uneven 
development of the population size of the FSAs due to changes in the economic environment, which 
may differentiate the geographical structure of the contact networks from reality. To highlight the 
impact of the treatment-as-prevention strategies applied during the prediction period and to make a 
better comparison, we assumed that all CHB patients who are eligible and ready for treatment can begin 
to receive TAF in early 2017. However, TAF was not allowed to enter the Canadian market until the 
second half of 2017. We assumed that the vaccination rate of the immigrants before immigrating to 
Canada is similar to that of Canadian-born people at the corresponding age, which may not be consistent 
with the actual situation. Although HBV is known to be a virus that is commonly transmitted through 
maternal-child contact, sexual activities, and injection drug use, our model only considered sexual 
transmission among heterosexual partners, which may underestimate the incidence and prevalence of 
future HBV-related health outcomes. However, a published article indicates that perinatal or horizontal 
infection in early childhood occurs mainly in high-prevalence regions of hepatitis B such as Asia and 
Africa.2 In low-prevalence regions such as Canada, sexual behaviors and injection drug use between 
adolescents and adults are the main routes of HBV transmission.2 In addition, our program structure 
has provided a framework for adding perinatal, horizontal, and homosexual transmissions in the future. 
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Although BSC alone (which is equivalent to not receiving any antiviral treatment) is unreasonable 
to be considered as a strategy to deal with CHB as both TDF and ETV have been listed as reimbursed 
drugs in Ontario, decision-makers may also be interested in how much more effectively 
TDF→ETV→BSC can eliminate AHB incidence and CHB prevalence in Ontario until 2030 compared 
with having no antiviral treatment at all. To figure this out, an analysis was performed in a similar 
manner to Section 3.2.3, and the results showed that the reported incidence of AHB resulting from 
TDF→ETV→BSC was slightly lower than that of BSC in most of the years predicted (Figure B.7). 
Figure B.8 shows how the magnitude of actual CHB prevalence resulting from TDF→ETV→BSC is 
greater than that resulting from BSC. Overall, the prevalence rates resulting from TDF→ETV→BSC 
was lower than that resulting from BSC. However, the variation in the prevalence rates between having 
treatment and not having treatment was almost negligible, which is less than 0.2 per 100,000 
population. Although TDF→ETV→BSC was found to be the most cost-effective strategy for treating 
CHB infections in Chapter 2, it was not found to have a significant difference in reducing the prevalence 
and incidence of HBV-related health outcomes compared with BSC alone. This may be due to the low 
HBV diagnostic rate (58%) and the low post-diagnosis treatment rate (40.7%) in Canada,73 as well as 
the non-100% viral suppression rates of the drugs.14,15,35 
By combining multi-agent systems and complex networks, we developed a complex network model 
that reflects the dynamics of HBV transmission, which enables forecasting of the epidemiology of HBV 
for policy-level decision making in Canada. The results suggest that current treatment-as-prevention 
strategies do not play a significant role in achieving the WHO’s goals of eliminating new CHB cases 
and CHB deaths.27 Some potential curable CHB treatments are currently in clinical trials.92 As these 
treatments prepare to enter the market, the analysis can be run again. Further analysis can be conducted 
to assess whether the goals set by the WHO can be achieved through other interventions, such as 






4.1 Summary of Results 
The results generated by the STM described in Chapter 2 shows that TDF→ETV→BSC is relatively 
likely to be the most cost-effective treatment option for both HBeAg-positive and HBeAg-negative 
CHB patients, which is consistent with the AASLD guidelines.17 ETV→TDF→BSC is also a good 
treatment strategy for HBeAg-positive patients. Strategies involving TAF are unlikely to be a rational 
choice for treating CHB infections as the price of TAF is more than four times that of TDF, but its 
efficacy is not comprehensively better than TDF. Public drug plans are therefore not recommended to 
reimburse TAF at the current price. 
The ABM described in Chapter 3 predicted that the actual prevalence of CHB in Ontario would 
decrease by 11.5% from 2017 to 2030 if all CHB patients eligible and ready for treatment begin to 
receive TDF→ETV→BSC or TAF→ETV→BSC after 2016. The reported incidence of AHB and the 
actual incidence of CHB are expected to fall by 48.9% and 52.2% from 2017 to 2030, respectively. The 
actual incidence of liver-related death is expected to rise by 12.3% from 2017 to 2030, regardless of 
the treatment-as-prevention strategies considered. The model predicted that the percentages of decline 
in new CHB cases and liver-related deaths from 2017 to 2030 would be 37.8% and 77.3% lower than 
the percentages that the WHO is targeting, respectively.27 Although TAF→ETV→BSC was found to 
be the most effective strategy for treating CHB infections in Chapter 2, it was not found to be 
significantly different from TDF→ETV→BSC in reducing the prevalence and incidence of HBV-
related health outcomes in Chapter 3. Since receiving antiviral treatment did not show clear differences 
from no antiviral treatment, current treatment-as-prevention strategies do not play a significant role in 
achieving the WHO goals of eliminating new CHB cases and CHB deaths. 
4.2 Thesis Contributions 
The vast majority of analyses in the literature regarding HBV infection are unable to predict the 
prevalence of CHB at future time points,19-24 and CHB-related analyses based on models other than 
STMs are limited. In order to fill this knowledge gap, this thesis accomplished the first analysis of 
hepatitis B that is built upon an ABM. Since HBV is highly contagious, finding and understanding 
strategies that can limit human-to-human transmission in a region is critical to reducing the global 
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prevalence of CHB. By combining multi-agent systems and complex networks, we developed the first 
AMB that can simulate HBV transmission between individuals through contact networks based on real 
demographic data from Ontario, which helps Canada move towards the goals set by the WHO.27 
Most CHB patients must continue to be treated for the rest of their lives.1 If they are not being treated 
effectively, they are likely to develop severe liver diseases such as HCC.2 Although TAF has been 
identified as a preferred therapy for patients with CHB in the guidelines released by the AASLD and 
the EASL due to clinical benefits,17,26 its cost-effectiveness compared with other HBV treatment options 
was previously unknown. This thesis produced the first cost-effectiveness analysis of hepatitis B that 
is built upon an STM that considers treatment strategies involving TAF and incorporated efficacy 
outcomes of the treatments from the latest systematic review and network meta-analysis.35 We also 
developed the first STM that takes into account the impact of treatment-related SAEs on the costs and 
utilities. This would not only update people's perception of the existing CHB drugs but also provide 
policy-level support for achieving CHB-related goals. 
4.3 Future Work 
As long-term follow-up efficacy outcomes of TAF are unavailable, future studies should incorporate 
more sophisticated long-term data as it becomes available to find the optimal treatment strategy for 
CHB infections. The impact of differences in people's income levels and education levels on partner 
selection and disease progression can also be considered in the two models. Future research can further 
enhance the ABM developed in this thesis (by adding perinatal and horizontal infections, homosexual 
and bisexual networks, and HBV transmission associated with injection drug use) and optimize our 
analyses to find out which combinations of interventions (such as combination strategies involving 
screening and vaccination) can most likely achieve the goals of CHB elimination. Costs and utilities 
can also be incorporated into the ABM to assess the cost-effectiveness of HBV elimination strategies 
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Additional Results Generated by the State-transition Model 
Table A.1 Health Outcomes of 1,000 Patients Initiated with Non-cirrhotic Chronic Hepatitis B 
Strategy 
DC (Number Prevented If 
Using 
TDF→ETV→BSC) 




(Number Prevented If 
Using TDF→ETV→BSC) 
Liver-related Death Caused 
by DC (Number Prevented If 
Using TDF→ETV→BSC) 
Liver-related Death Caused 
by HCC (Number Prevented 
If Using TDF→ETV→BSC) 
HBeAg-positive Cohort 
TAF→BSC 323 (16)  231 (10)  423 (23)  200 (12)  173 (8)  
TDF→BSC 332 (25)  237 (16)  434 (34)  205 (17)  178 (13)  
ETV→BSC 363 (56)  260 (39)  478 (78)  225 (37)  196 (31)  
TAF→ETV→BSC 299 (-8)  215 (-6)  389 (-11)  183 (-5)  161 (-4)  
TDF→ETV→BSC 307   221   400   188   165   
ETV→TAF→BSC 298 (-9)  215 (-6)  389 (-11)  183 (-5)  161 (-4)  
ETV→TDF→BSC 306 (-1)  220 (-1)  399 (-1)  188 (0)  164 (-1)  
HBeAg-negative Cohort 
TAF→BSC 265 (11)  178 (8)  314 (17)  154 (8)  129 (7)  
TDF→BSC 276 (22)  187 (17)  329 (32)  160 (14)  136 (14)  
ETV→BSC 329 (75)  229 (59)  406 (109)  196 (50)  169 (47)  
TAF→ETV→BSC 244 (-10)  162 (-8)  284 (-13)  140 (-6)  117 (-5)  
TDF→ETV→BSC 254   170   297   146   122   
ETV→TAF→BSC 244 (-10)  162 (-8)  284 (-13)  140 (-6)  117 (-5)  
ETV→TDF→BSC 254 (0)   170 (0)   297 (0)   146 (0)   122 (0)   
 
BSC, best supportive care; DC, decompensated cirrhosis; ETV, entecavir; HBeAg, hepatitis B envelope antigen; HCC, hepatocellular carcinoma; TAF, tenofovir alafenamide; TDF, 




Figure A.1 One-way Sensitivity Analyses: Tornado Diagrams 
(a) HBeAg-positive Cohort: TAF→ETV→BSC vs TDF→ETV→BSC 
 
(b) HBeAg-positive Cohort: TDF→ETV→BSC vs TDF→BSC 
 
(c) HBeAg-positive Cohort: ETV→TDF→BSC vs TDF→ETV→BSC 
 




Figure A.1 Continued 
(e) HBeAg-negative Cohort: TDF→BSC vs ETV→BSC 
 
∞ indicates that changing the value of the parameter within the given range will certainly alter the conclusion. Red bars and 
blue bars represent the results of the high and low values of the parameters, respectively. 
BSC, best supportive care; ETV, entecavir; CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompensated 
cirrhosis; HBeAg, hepatitis B envelope antigen; HBeAg-, hepatitis B envelope antigen-negative; HBeAg+, hepatitis B 
envelope antigen-positive; HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; TAF, tenofovir 




Figure A.2 Probabilistic Sensitivity Analyses: Cost-effectiveness Acceptability Curves 
(a) HBeAg-positive Cohort 
 
(b) HBeAg-negative Cohort 
 





Table A.2 Threshold Analysis Cost-effectiveness Results 
HBeAg-positive Cohort; Unit Price of TAF: $13.02 
Strategy Costs ΔCosts QALYs ΔQALYs ICER ($/QALY) 
TDF→BSC $274,743.42  22.8618   
TDF→ETV→BSC $276,409.87 $1,666.46 23.5859 0.7241 2,301.27 
TAF→ETV→BSC $284,289.50 $7,879.62 23.7435 0.1576 50,000.00 
Absolutely Dominated Strategies (all referencing TDF→BSC) 
ETV→BSC $275,065.00 $321.58 22.0516 -0.8102 -396.92 
ETV→TDF→BSC $276,636.53 $1,893.11 23.5842 0.7224 2,620.63 
TAF→BSC $282,638.92 $7,895.50 23.0378 0.1760 44,859.61 
ETV→TAF→BSC $285,933.06 $11,189.64 23.7328 0.8711 12,846.11 
HBeAg-negative Cohort; Unit Price of TAF: $6.20 
Strategy Costs ΔCosts QALYs ΔQALYs ICER ($/QALY) 
ETV→BSC $252,171.57  20.6444   
TDF→BSC $259,274.75 $7,103.18 21.7453 1.1009 6,452.03 
TDF→ETV→BSC $263,141.73 $3,866.98 22.1941 0.4488 8,616.22 
ETV→TAF→BSC $269,622.80 $6,481.07 22.3238 0.1296 50,000.00 
TAF→ETV→BSC $269,809.35 $186.54 22.3243 0.0005 385,475.31 
Absolutely Dominated Strategies (all referencing ETV→BSC) 
ETV→TDF→BSC $263,272.76 $11,101.19 22.1938 1.5494 7,164.99 
TAF→BSC $266,189.07 $14,017.51 21.9112 1.2668 11,065.70 
HBeAg-negative Cohort; Unit Price of TAF: $7.82 
Strategy Costs ΔCosts QALYs ΔQALYs ICER ($/QALY) 
ETV→BSC $252,171.57  20.6444   
TDF→BSC $259,274.75 $7,103.18 21.7453 1.1009 6,452.03 
TDF→ETV→BSC $263,141.73 $3,866.98 22.1941 0.4488 8,616.22 
ETV→TAF→BSC $276,103.88 $12,962.15 22.3238 0.1296 100,000.00 
TAF→ETV→BSC $276,731.28 $627.40 22.3243 0.0005 1,296,470.29 
Absolutely Dominated Strategies (all referencing ETV→BSC) 
ETV→TDF→BSC $263,272.76 $11,101.19 22.1938 1.5494 7,164.99 
TAF→BSC $273,111.01 $20,939.44 21.9112 1.2668 16,530.01 
 
BSC, best supportive care; ETV, entecavir; HBeAg, hepatitis B envelope antigen; ICER, incremental cost-effectiveness ratio; 





Additional Results Generated by the Agent-based Model 
Figure B.1 Impact of Changes in the HBV Prevalence Rates in Immigrant-sourced Regions on HBV-
related Health Outcomes 
(a) Actual Prevalence of Chronic Hepatitis B 
 





Figure B.1 Continued 
(c) Actual Incidence of Liver-related Death 
 
BSC, best supportive care; ETV, entecavir; HBV, hepatitis B virus; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil 
fumarate. 
 
Figure B.2 Impact of Changes in the Number of Newborns on HBV-related Health Outcomes 





Figure B.2 Continued 
(b) Reported Incidence of Acute Hepatitis B 
 
(c) Actual Incidence of Liver-related Death 
 






Figure B.3 Impact of Changes in the HBV Vaccination Rate in Immigrants Aged 14 to 79 on HBV-
related Health Outcomes 
(a) Actual Prevalence of Chronic Hepatitis B 
 








Figure B.3 Continued 
(c) Actual Incidence of Liver-related Death 
 
BSC, best supportive care; ETV, entecavir; HBV, hepatitis B virus; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil 
fumarate. 
 
Figure B.4 Impact of Changes in the HBV Diagnostic Rate in Immigrants on HBV-related Health 
Outcomes 




Figure B.4 Continued 
(b) Reported Incidence of Acute Hepatitis B 
 
(c) Actual Incidence of Liver-related Death 
 






Figure B.5 Impact of Changes in the Treatment Rate in HBV-infected Patients Who Are Eligible for 
Treatment on HBV-related Health Outcomes 
(a) Actual Prevalence of Chronic Hepatitis B 
 








Figure B.5 Continued 
(c) Actual Incidence of Liver-related Death 
 
BSC, best supportive care; ETV, entecavir; HBV, hepatitis B virus; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil 
fumarate. 
 
Figure B.6 Impact of Changes in the efficacy of the Treatments on HBV-related Health Outcomes 





Figure B.6 Continued 
(b) Reported Incidence of Acute Hepatitis B 
 
(c) Actual Incidence of Liver-related Death 
 







Figure B.7 Reported Incidence of Acute Hepatitis B 
 
BSC, best supportive care; ETV, entecavir; TDF, tenofovir disoproxil fumarate. 
 
Figure B.8 Additional Cases of Chronic Hepatitis B Compared with BSC 
 
BSC, best supportive care; ETV, entecavir; TDF, tenofovir disoproxil fumarate. 
